BGNE

BeiGene, Ltd. (BGNE)

Last Price$226.70.0%
Market Cap$1,846.9M
LTM ROIC - WACC
(45.1%)
5Y avg
(201.9%)
Biotechnology industry median
(133.4%)
Stock quality & Intrinsic value
5/10
11.4% undervalued

BeiGene, Ltd. ROIC - WACC

Annual
Quarterly
LTM
Industry median
Company stand-alone
BGNE
Healthcare
Crunching data... Almost there!
Dec'13Dec'14Dec'15Dec'16Dec'17Dec'18Dec'19Dec'20Dec'21Dec'22Dec'23
ROIC - WACC
(128.8%)
(411.6%)
(14,989.9%)
(2,015.8%)
(306.1%)
(546.5%)
(359.7%)
(424.5%)
(161.5%)
(155.5%)
(89.1%)
BGNE
Key metrics and insights to make informed decisions.
View full analysis
Overvalued or undervalued?
Check the intrinsic value for BGNE and see if it's the right time to invest.
Dive in

BeiGene, Ltd. (BGNE) ROIC - WACC comparison analysis

Crunching data... Almost there!

BGNE key stats

USD
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
Crunching data... Almost there!

Discover more Stock Ideas

FAQ

1) What is BeiGene, Ltd.'s ROIC - WACC?

As of today, Microsoft Corp's last 12-month ROIC - WACC is (45.1%), based on the financial report for Sep 30, 2024 (Q3 2024). The average annual ROIC - WACC for BeiGene, Ltd. have been (145.7%) over the past three years, and (212.0%) over the past five years.

2) Is BeiGene, Ltd.'s ROIC - WACC Good?

As of today, BeiGene, Ltd.'s ROIC - WACC is (45.1%), which is higher than industry median of (133.4%). It indicates that BeiGene, Ltd.'s ROIC - WACC is Good.

3) How does BeiGene, Ltd.'s ROIC - WACC compare to its peers?

As of today, BeiGene, Ltd.'s ROIC - WACC is (45.1%), which is lower than peer median of (7.4%). The list of peers includes UTHR, NVO, REGN, RPRX, ALNY, INCY, VRTX, BNTX, SMMT, ARGX.